These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 22547083)

  • 21. In vitro modulatory effects on three major human cytochrome P450 enzymes by multiple active constituents and extracts of Centella asiatica.
    Pan Y; Abd-Rashid BA; Ismail Z; Ismail R; Mak JW; Pook PC; Er HM; Ong CE
    J Ethnopharmacol; 2010 Jul; 130(2):275-83. PubMed ID: 20457244
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High warfarin sensitivity in carriers of CYP2C9*35 is determined by the impaired interaction with P450 oxidoreductase.
    Lee MY; Borgiani P; Johansson I; Oteri F; Mkrtchian S; Falconi M; Ingelman-Sundberg M
    Pharmacogenomics J; 2014 Aug; 14(4):343-9. PubMed ID: 24322786
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Polymorphic variants (CYP2C9*3 and CYP2C9*5) and the F114L active site mutation of CYP2C9: effect on atypical kinetic metabolism profiles.
    Tracy TS; Hutzler JM; Haining RL; Rettie AE; Hummel MA; Dickmann LJ
    Drug Metab Dispos; 2002 Apr; 30(4):385-90. PubMed ID: 11901091
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Characterization of CYP2C19 and CYP2C9 from human liver: respective roles in microsomal tolbutamide, S-mephenytoin, and omeprazole hydroxylations.
    Lasker JM; Wester MR; Aramsombatdee E; Raucy JL
    Arch Biochem Biophys; 1998 May; 353(1):16-28. PubMed ID: 9578596
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identification of the polymorphically expressed CYP2C19 and the wild-type CYP2C9-ILE359 allele as low-Km catalysts of cyclophosphamide and ifosfamide activation.
    Chang TK; Yu L; Goldstein JA; Waxman DJ
    Pharmacogenetics; 1997 Jun; 7(3):211-21. PubMed ID: 9241661
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of CYP2C9 and CYP2C19 polymorphisms on tolbutamide kinetics and the insulin and glucose response in healthy volunteers.
    Kirchheiner J; Bauer S; Meineke I; Rohde W; Prang V; Meisel C; Roots I; Brockmöller J
    Pharmacogenetics; 2002 Mar; 12(2):101-9. PubMed ID: 11875364
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cynomolgus monkey cytochrome P450 2C43: cDNA cloning, heterologous expression, purification and characterization.
    Mitsuda M; Iwasaki M; Asahi S
    J Biochem; 2006 May; 139(5):865-72. PubMed ID: 16751594
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Role of conserved Asp293 of cytochrome P450 2C9 in substrate recognition and catalytic activity.
    Flanagan JU; McLaughlin LA; Paine MJ; Sutcliffe MJ; Roberts GC; Wolf CR
    Biochem J; 2003 Mar; 370(Pt 3):921-6. PubMed ID: 12482324
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CYP2C9*2 allele increases risk for hypoglycemia in POR*1/*1 type 2 diabetic patients treated with sulfonylureas.
    Ragia G; Tavridou A; Elens L; Van Schaik RH; Manolopoulos VG
    Exp Clin Endocrinol Diabetes; 2014 Jan; 122(1):60-3. PubMed ID: 24464600
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of histidine-tag and R457H and E580Q mutations on catalytic activity of recombinant human cytochrome P450 oxidoreductase.
    Niwa T; Minami K; Katagiri M
    Drug Metab Pharmacokinet; 2012; 27(1):150-4. PubMed ID: 22123124
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Characterizing the effect of cytochrome P450 (CYP) 2C8, CYP2C9, and CYP2D6 genetic polymorphisms on stereoselective N-demethylation of fluoxetine.
    Wang Z; Wang S; Huang M; Hu H; Yu L; Zeng S
    Chirality; 2014 Mar; 26(3):166-73. PubMed ID: 24464553
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical drugs undergoing polymorphic metabolism by human cytochrome P450 2C9 and the implication in drug development.
    He SM; Zhou ZW; Li XT; Zhou SF
    Curr Med Chem; 2011; 18(5):667-713. PubMed ID: 21182487
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Catalytic activities of human cytochrome P450 2C9*1, 2C9*3 and 2C9*13.
    Guo Y; Wang Y; Si D; Fawcett PJ; Zhong D; Zhou H
    Xenobiotica; 2005 Sep; 35(9):853-61. PubMed ID: 16308280
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vitro functional characterization of 37 CYP2C9 allelic isoforms found in Chinese Han population.
    Dai DP; Wang YH; Wang SH; Geng PW; Hu LM; Hu GX; Cai JP
    Acta Pharmacol Sin; 2013 Nov; 34(11):1449-56. PubMed ID: 24077631
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Functional characterization of novel allelic variants of CYP2C9 recently discovered in southeast Asians.
    DeLozier TC; Lee SC; Coulter SJ; Goh BC; Goldstein JA
    J Pharmacol Exp Ther; 2005 Dec; 315(3):1085-90. PubMed ID: 16099926
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tolbutamide, flurbiprofen, and losartan as probes of CYP2C9 activity in humans.
    Lee CR; Pieper JA; Frye RF; Hinderliter AL; Blaisdell JA; Goldstein JA
    J Clin Pharmacol; 2003 Jan; 43(1):84-91. PubMed ID: 12520632
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Enzyme source effects on CYP2C9 kinetics and inhibition.
    Kumar V; Rock DA; Warren CJ; Tracy TS; Wahlstrom JL
    Drug Metab Dispos; 2006 Nov; 34(11):1903-8. PubMed ID: 16928789
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Construction of Salmonella typhimurium YG7108 strains, each coexpressing a form of human cytochrome P450 with NADPH-cytochrome P450 reductase.
    Fujita K; Nakayama K; Yamazaki Y; Tsuruma K; Yamada M; Nohmi T; Kamataki T
    Environ Mol Mutagen; 2001; 38(4):329-38. PubMed ID: 11774365
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Co-expression of recombinant human CYP2C9 with human cytochrome P450 reductase in protease deficient S. cerevisiae strain at a higher scale yields an enzyme of higher specific activity.
    Rao KN; Suman SK; Kiran YR; Kuanr AR; Gupta AK; Bhalla K; Kumar V; Kundu P; Arora K; Soni R
    Drug Metab Lett; 2010 Dec; 4(4):246-53. PubMed ID: 20722625
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Characterization of Interactions Among CYP1A2, CYP2B4, and NADPH-cytochrome P450 Reductase: Identification of Specific Protein Complexes.
    Connick JP; Reed JR; Backes WL
    Drug Metab Dispos; 2018 Mar; 46(3):197-203. PubMed ID: 29233819
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.